Ponticelli Claudio, Moroni Gabriella
Former Director Renal Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
Nephrological Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
J Clin Med. 2018 Dec 15;7(12):552. doi: 10.3390/jcm7120552.
Women affected by autoimmune diseases, organ transplantation, or neoplasia need to continue immunosuppressive treatment during pregnancy. In this setting, not only a careful planning of pregnancy, but also the choice of drugs is critical to preventing maternal complications and minimizing the fetal risks. Some immunosuppressive drugs are teratogenic and should be replaced even before the pregnancy, while other drugs need to be managed with caution to prevent fetal risks, including miscarriage, intrauterine growth restriction, prematurity, and low birth weight. In particular, the increasing use of biologic agents raises the question of their compatibility with reproduction. In this review we present data on the indication and safety in pregnancy of the most frequently used immunosuppressive drugs.
患有自身免疫性疾病、接受过器官移植或患有肿瘤的女性在孕期需要继续进行免疫抑制治疗。在这种情况下,不仅要精心规划妊娠,药物的选择对于预防母体并发症和将胎儿风险降至最低也至关重要。一些免疫抑制药物具有致畸性,甚至在怀孕前就应更换,而其他药物则需要谨慎使用以预防胎儿风险,包括流产、宫内生长受限、早产和低出生体重。特别是,生物制剂使用的增加引发了其与生殖兼容性的问题。在本综述中,我们呈现了关于最常用免疫抑制药物在孕期的适应证和安全性的数据。